Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

Understanding dementia and Alzheimer’s disease is essential for maintaining a proactive approach to our well-being.

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought ...

The sleep aid Ambien could be allowing toxic proteins to pollute the brain, potentially increasing a person’s risk of ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...

A new study reveals that the sleep aid Ambien (zolpidem) may increase Alzheimer’s risk by disrupting the brain's ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...